Pulmonary arterial hypertension
Not yet recruitingStudy of combination therapy with an endothelin receptor antagonist, phosphodiesterase‑5 inhibitor, and sotatercept in newly diagnosed pulmonary arterial hypertension
Study of combination therapy with an endothelin receptor antagonist, phosphodiesterase‑5 inhibitor, and sotatercept in newly diagnosed pulmonary arterial hypertension
- Disease:Pulmonary arterial hypertension
- Substances:Sotatercept
Germany- Participants:18–64 years · 65+ years
- Substances:Sotatercept
- Sponsor:Philipps-Universitaet Marburg












